Orthocell Ltd (OCC) - Cash Flow Conversion Efficiency

Latest as of June 2025: -0.211x

Based on the latest financial reports, Orthocell Ltd (OCC) has a cash flow conversion efficiency ratio of -0.211x as of June 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow (AU$-3.07 Million ≈ $-2.17 Million USD) by net assets (AU$14.57 Million ≈ $10.31 Million USD). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.

Orthocell Ltd - Cash Flow Conversion Efficiency Trend (2013–2025)

This chart illustrates how Orthocell Ltd's cash flow conversion efficiency has evolved over time, based on yearly financial data. Read OCC liabilities breakdown for a breakdown of total debt and financial obligations.

Orthocell Ltd Competitors by Cash Flow Conversion Efficiency

The table below lists competitors of Orthocell Ltd ranked by their cash flow conversion efficiency.

Company Cash Flow Conversion Efficiency
Melar Acquisition Corp. I Class A Ordinary Shares
NASDAQ:MACI
-0.001x
D-Link (India) Limited
NSE:DLINKINDIA
0.090x
Hansol Technics
KO:004710
0.037x
Astron Corporation Ltd
AU:ATR
-0.020x
Sunjin
KO:136490
0.039x
Lemtech Holdings Co Ltd
TW:4912
-0.017x
Sparebanken Ost
OL:SPOG
0.022x
Strawberry Fields REIT LLC
NYSE MKT:STRW
0.330x

Annual Cash Flow Conversion Efficiency for Orthocell Ltd (2013–2025)

The table below shows the annual cash flow conversion efficiency of Orthocell Ltd from 2013 to 2025. For the full company profile with market capitalisation and key ratios, see how much is Orthocell Ltd worth.

Year Net Assets Operating Cash Flow Cash Flow Conversion Efficiency Change
2025-06-30 AU$14.57 Million
≈ $10.31 Million
AU$-8.68 Million
≈ $-6.14 Million
-0.596x +58.47%
2024-06-30 AU$4.53 Million
≈ $3.21 Million
AU$-6.51 Million
≈ $-4.60 Million
-1.435x -160.48%
2023-06-30 AU$6.15 Million
≈ $4.35 Million
AU$14.59 Million
≈ $10.33 Million
2.373x +475.40%
2022-06-30 AU$9.90 Million
≈ $7.01 Million
AU$-6.26 Million
≈ $-4.43 Million
-0.632x -130.23%
2021-06-30 AU$16.87 Million
≈ $11.94 Million
AU$-4.63 Million
≈ $-3.28 Million
-0.275x -9.18%
2020-06-30 AU$20.90 Million
≈ $14.79 Million
AU$-5.26 Million
≈ $-3.72 Million
-0.251x +35.49%
2019-06-30 AU$10.72 Million
≈ $7.59 Million
AU$-4.18 Million
≈ $-2.96 Million
-0.390x +80.09%
2018-06-30 AU$2.37 Million
≈ $1.68 Million
AU$-4.64 Million
≈ $-3.29 Million
-1.958x -159.49%
2017-06-30 AU$4.71 Million
≈ $3.33 Million
AU$-3.56 Million
≈ $-2.52 Million
-0.754x -10.96%
2016-06-30 AU$4.88 Million
≈ $3.46 Million
AU$-3.32 Million
≈ $-2.35 Million
-0.680x -7.70%
2015-06-30 AU$4.38 Million
≈ $3.10 Million
AU$-2.77 Million
≈ $-1.96 Million
-0.631x +97.26%
2014-06-30 AU$76.19K
≈ $53.91K
AU$-1.75 Million
≈ $-1.24 Million
-23.009x -8434.14%
2013-06-30 AU$1.08 Million
≈ $762.57K
AU$-290.57K
≈ $-205.60K
-0.270x --

About Orthocell Ltd

AU:OCC Australia Biotechnology
Market Cap
$172.77 Million
AU$244.18 Million AUD
Market Cap Rank
#17076 Global
#498 in Australia
Share Price
AU$0.90
Change (1 day)
+0.56%
52-Week Range
AU$0.72 - AU$1.59
All Time High
AU$1.75
About

Orthocell Limited, a regenerative medicine company, develops and commercializes cell therapies and biological medical devices for the repair of various bone and soft tissue injuries in Australia and internationally. It offers Ortho Autologous Chondrocyte Implantation, a cartilage cell therapy for treatment of articular cartilage defects in the knee and ankle; Striate+, a resorbable collagen membr… Read more